Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
Analysis of Hepatitis C Viral Kinetics and Viramidine Pharmacokinetics Utilizing Two Treatment Regimens in Therapy-Naive Patients With Chronic Hepatitis C
Sponsor: Bausch Health Americas, Inc.
Terminated
Dose levels were determined to be subtherapeutic
Other terminated trials from Bausch Health Americas, Inc.
- AKN · Phase PHASE3 · Apr 2024
- Irritable Bowel Syndrome · Phase PHASE2 · Nov 2021
- Severe Hepatic Impairment · Phase PHASE4 · Feb 2020
- Crohn's Disease · Phase PHASE3 · Oct 2017
- Crohn's Disease · Phase PHASE3 · Aug 2017
More terminations from Bausch Health Americas, Inc.
A PHASE2 clinical study on Hepatitis C, Chronic, this trial is terminated or withdrawn. The trial is conducted by Bausch Health Americas, Inc. and has accumulated 8 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jun 2019 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .